Related Experiment Videos
New approaches to the systemic treatment of melanoma
S Chowdhury1, M M Vaughan, M E Gore
1Melanoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3, UK.
Abstract:
Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemotherapy can result in higher response rates there is no response duration or survival advantage. Phase II studies have suggested that combining chemotherapy with biological response modifiers may result in higher response rates, in the order of 50% and the results of two large randomized trials investigating this approach are awaited. Adjuvant trials currently focus on interferon and/or vaccine strategies. Further data are required before any adjuvant treatment can be regarded as standard.
Insights
Metastatic melanoma remains incurable. Combining chemotherapy with biological response modifiers shows promise for higher response rates, though further data from randomized trials are needed to confirm benefits.
Area of Science:
- Oncology
- Cancer Research
Background:
- Metastatic melanoma has a poor prognosis with limited treatment options.
- Current chemotherapy offers short-lived responses in a minority of patients.
- Dacarbazine (DTIC) shows modest activity as a single agent.
Purpose of the Study:
- To review current treatment strategies for metastatic melanoma.
- To evaluate the potential of combining chemotherapy with biological response modifiers.
- To discuss ongoing adjuvant treatment trials.
Main Methods:
- Review of existing clinical trial data and literature.
- Analysis of response rates and survival data for various treatment regimens.
- Focus on Phase II study findings and planned randomized trials.
Main Results:
- Chemotherapy provides objective responses in a small percentage of patients with short durations.
- Dacarbazine (DTIC) has response rates of 15-20%.
- Phase II studies suggest combining chemotherapy with biological response modifiers may achieve response rates around 50%.
Conclusions:
- Metastatic melanoma treatment remains challenging.
- Combining chemotherapy with biological response modifiers is a promising approach requiring further validation.
- Adjuvant therapies like interferon and vaccines are under investigation but not yet standard care.